Rights and permissions
About this article
Cite this article
Degarelix cheaper as first-line therapy in prostate cancer. Pharmacoecon. Outcomes News 647, 5 (2012). https://doi.org/10.2165/00151234-201206470-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206470-00012